Cadonilimab  (Synonyms: AK104)

Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC)^[1][2][3][4].

IgG1-kappa-[scFv-heavy-lambda]2

Human IgG1 kappa, Isotype Control

Human

CTLA4 & PDCD1

Cadonilimab (0-100 nM, 10-120 min) maintains a high affinity for Jurkat-CTLA4 and Jurkat-PD1 cells in vitro after iodine modification^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cadonilimab (3.7 MBq, tail i.v., a single dose) modified with ¹²⁴I largely enriches in the spleen, tumor sites and results in enrichment of PD1/CTLA4 positive immune cells at the tumor sites in humanized mice with MC38-hPD-L1 cell xenografts^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1493  [NCBI] & 5133  [NCBI]

P16410 & Q15116

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

198.64 kDa

2394841-59-7

Liquid

Colorless to light yellow

[Cadonilimab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  IgG1-kappa-[scFv-heavy-lambda]2

• 
  Immobilized Cadonilimab can bind Human PD-1 Protein (ECD, His Tag). The EC₅₀ for this effect is 0.197 ng/mL.
• 
  Immobilized Cadonilimab can bind Human CTLA-4 Protein (His Tag). The EC₅₀ for this effect is 3.07 ng/mL.
• 
  Immobilized Cadonilimab can bind Human CTLA-4 Protein (His Tag). The EC₅₀ for this effect is 3.07 ng/mL. Flow Cytometry analysis of Raji cells labelling CTLA4 (red) with Cadonilimab (anti-CTLA4) (HY-P99117). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
• 
  Flow Cytometry analysis of THP-1 cells labelling PDCD1 (red) with Cadonilimab (anti-PDCD1) (HY-P99117). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Antonarelli G, et al. Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies. Pharmaceuticals (Basel). 2021 Aug 31;14(9):884.  [Content Brief]

  [2]. Kaplon H, et al. Antibodies to watch in 2022. MAbs. 2022 Jan-Dec;14(1):2014296.  [Content Brief]

  [3]. Chen PY, et al. Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab. Front Immunol. 2023 Aug 3;14:1188523.  [Content Brief]

  [4]. Hou X, et al. Preclinical imaging evaluation of a bispecific antibody targeting hPD1/CTLA4 using humanized mice. Biomed Pharmacother. 2024 Jun;175:116669.  [Content Brief]